Ibuprofen business continues to drag profitability
Ibuprofen recorded negative EBITDA again; strategic options may not yield favorable outcome, prolonging losses.
SOLARA / Q4-FY26 / risks
Keep the risk register visible.
Solara Active Pharma Sciences · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
R&D spend not yielding near-term results
Despite ₹200 crore R&D spend over 4-5 years, no new profitable product launched; new DMFs will only commercialize from FY29.
Vizag facility mothballed with ongoing costs
Vizag site mothballed since 2024 incurs ₹12-15 crore annual maintenance cost with no revenue.
Customer concentration in base business
Top 15-20 products contribute 75-80% of base business revenue; loss of any key customer could impact performance.